Trinity Biotech Partners with Latch Medical, Makes Equity Investment

Trinity Biotech plc announced a strategic collaboration agreement with Latch Medical Limited to develop next-generation metabolic health solutions. The partnership will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative Pharma Latch™ intradermal drug delivery technology. This aims to create personalized and responsive treatment approaches for conditions like diabetes and obesity. As part of the collaboration, Trinity Biotech will also make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors.